X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Rating of “Hold” by Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned a consensus rating of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $34.50.

Several research firms have weighed in on XFOR. Wall Street Zen downgraded X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Stifel Nicolaus set a $10.00 price objective on shares of X4 Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 5th. Finally, Zacks Research cut X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in X4 Pharmaceuticals during the 4th quarter worth $90,000. Susquehanna Portfolio Strategies LLC purchased a new stake in X4 Pharmaceuticals in the 4th quarter valued at approximately $173,000. Perceptive Advisors LLC purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at $25,258,000. Man Group plc acquired a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth about $97,000. Finally, Balyasny Asset Management L.P. acquired a new stake in X4 Pharmaceuticals during the fourth quarter worth approximately $258,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Price Performance

Shares of XFOR opened at $3.33 on Wednesday. X4 Pharmaceuticals has a 1-year low of $1.35 and a 1-year high of $11.47. The company has a debt-to-equity ratio of 1.23, a current ratio of 5.65 and a quick ratio of 5.48. The firm has a 50-day simple moving average of $3.70 and a two-hundred day simple moving average of $3.59. The stock has a market cap of $291.18 million, a PE ratio of -0.33 and a beta of 0.43.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.